Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma
- 190 Downloads
Tumor-associated gene expression in peripheral blood reflects the presence of circulating hepatocellular carcinoma (HCC) cells and might be associated with aggressive features of HCC. We assessed the prognostic significance of alpha-fetoprotein (AFP) and human telomerase reverse transcriptase protein (hTERT) mRNA expression in the peripheral blood of HCC patients.
About 343 HCC patients, treated at the National Cancer Center, Korea, were included in this study. We measured AFP and hTERT mRNA levels in peripheral blood using quantitative real-time reverse transcription polymerase chain reaction. The association between the expression of each gene and survival was analyzed.
AFP and hTERT mRNA were detected in 204 (59.5%) and 48 (14.0%) patients with HCC, respectively. The mean AFP copy number was 203 copies/μL (range 0–19992 copies/μL) and that of hTERT was 26 copies/μL (0–1711 copies/μL). AFP mRNA expression was correlated with the number of tumors (P = 0.05), but there were no significant association between hTERT expression and clinical features. There was also no relationship between overall survival and AFP (P = 0.08) or hTERT (P = 0.67) mRNA expression.
This is the first report to evaluate the association between peripheral blood hTERT mRNA expression, and survival of HCC patients. The results indicate that AFP and hTERT mRNA expression in peripheral blood may not be useful HCC prognostic markers.
KeywordsAlpha-fetoprotein (AFP) Human telomerase reverse transcriptase (hTERT) Circulating tumor cells Hepatocellular carcinoma (HCC) Survival Prognosis
- Cillo U, Navaglia F, Vitale A, Molari A, Basso D, Bassanello M, Brolese A, Zanus G, Montin U, D’Amico F, Ciarleglio FA, Carraro A, Bridda A, Burra P, Carraro P, Plebani M, D’Amico DF (2004) Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma. Clin Chim Acta 347:129–138. doi:10.1016/j.cccn.2004.04.032 PubMedCrossRefGoogle Scholar
- El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, McGlynn KA (2006) Treatment and outcomes of treating of hepatocellular carcinoma among medicare recipients in the United States: a population-based study. J Hepatol 44:158–166. doi:10.1016/j.jhep.2005.10.002 PubMedCrossRefGoogle Scholar
- Gross-Goupil M, Saffroy R, Azoulay D, Precetti S, Emile JF, Delvart V, Tindiliere F, Laurent A, Bellin MF, Bismuth H, Debuire B, Lemoine A (2003) Real-time quantification of AFP mRNA to assess hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma. Ann Surg 238:241–248PubMedGoogle Scholar
- Louha M, Poussin K, Ganne N, Zylberberg H, Nalpas B, Nicolet J, Capron F, Soubrane O, Vons C, Pol S, Beaugrand M, Berthelot P, Franco D, Trinchet JC, Brechot C, Paterlini P (1997) Spontaneous and iatrogenic spreading of liver-derived cells into peripheral blood of patients with primary liver cancer. Hepatology 26:998–1005. doi:10.1002/hep.510260430 PubMedCrossRefGoogle Scholar
- Miura N, Maeda Y, Kanbe T, Yazama H, Takeda Y, Sato R, Tsukamoto T, Sato E, Marumoto A, Harada T, Sano A, Kishimoto Y, Hirooka Y, Murawaki Y, Hasegawa J, Shiota G (2005) Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res 11:3205–3209. doi:10.1158/1078-0432.CCR-04-1487 PubMedCrossRefGoogle Scholar
- Sato S, Noguchi Y, Wada H, Fujita S, Nakamura S, Tanaka R, Nakada T, Hasegawa K, Nakagawa K, Koizumi F, Ono T, Nouso K, Jungbluth A, Chen YT, Old LJ, Shiratori Y, Nakayama E (2005) Quantitative real-time RT-PCR analysis of NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and tumors, and correlation of the protein expression with the mRNA copy number. Int J Oncol 26:57–63PubMedGoogle Scholar
- Ueno S, Tanabe G, Nuruki K, Hamanoue M, Komorizono Y, Oketani M, Hokotate H, Inoue H, Baba Y, Imamura Y, Aikou T (2002) Prognostic performance of the new classification of primary liver cancer of Japan (4th ed) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res 24:395–403. doi:10.1016/S1386-6346(02)00144-4 PubMedCrossRefGoogle Scholar
- Waguri N, Suda T, Nomoto M, Kawai H, Mita Y, Kuroiwa T, Igarashi M, Kobayashi M, Fukuhara Y, Aoyagi Y (2003) Sensitive and specific detection of circulating cancer cells in patients with hepatocellular carcinoma; detection of human telomerase reverse transcriptase messenger RNA after immunomagnetic separation. Clin Cancer Res 9:3004–3011PubMedGoogle Scholar
- Witzigmann H, Geissler F, Benedix F, Thiery J, Uhlmann D, Tannapfel A, Wittekind C, Hauss J (2002) Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma. Surgery 131:34–43. doi:10.1067/msy.2002.118954 PubMedCrossRefGoogle Scholar
- Wong IH, Yeo W, Leung T, Lau WY, Johnson PJ (2001) Circulating tumor cell mRNAs in peripheral blood from hepato cellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation. Cancer Lett 167:183–191. doi:10.1016/S0304-3835(01)00455-4 PubMedCrossRefGoogle Scholar